L6Y Stock Overview
Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wellfully Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0005 |
| 52 Week High | AU$0.016 |
| 52 Week Low | AU$0.0005 |
| Beta | -0.91 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| L6Y | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | 1.1% |
| 1Y | n/a | -21.6% | 6.5% |
Return vs Industry: Insufficient data to determine how L6Y performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how L6Y performed against the German Market.
Price Volatility
| L6Y volatility | |
|---|---|
| L6Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L6Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine L6Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Paul Peros | www.wellfully.net |
Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. The company is also involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations.
Wellfully Limited Fundamentals Summary
| L6Y fundamental statistics | |
|---|---|
| Market cap | €886.36k |
| Earnings (TTM) | -€4.68m |
| Revenue (TTM) | €997.10k |
0.9x
P/S Ratio-0.2x
P/E RatioIs L6Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L6Y income statement (TTM) | |
|---|---|
| Revenue | AU$1.66m |
| Cost of Revenue | AU$1.86m |
| Gross Profit | -AU$200.41k |
| Other Expenses | AU$7.60m |
| Earnings | -AU$7.80m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | -12.05% |
| Net Profit Margin | -469.00% |
| Debt/Equity Ratio | -98.7% |
How did L6Y perform over the long term?
See historical performance and comparison